Status:
COMPLETED
Tanezumab in Osteoarthritis of the Hip or Knee (2)
Lead Sponsor:
Pfizer
Conditions:
Osteoarthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
Eligibility Criteria
Inclusion
- Osteoarthritis of the hip or knee according to Kellgren-Lawrence x-ray grade of 2
Exclusion
- pregnancy or intent to become pregnant
- BMI greater than 39
- other severe pain, significant cardiac, neurological or psychiatric disease
Key Trial Info
Start Date :
June 9 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2010
Estimated Enrollment :
849 Patients enrolled
Trial Details
Trial ID
NCT00863304
Start Date
June 9 2009
End Date
August 16 2010
Last Update
May 17 2021
Active Locations (95)
Enter a location and click search to find clinical trials sorted by distance.
1
Greystone Medical Research, LLC
Birmingham, Alabama, United States, 35242
2
Saadat Ansari, MD
Huntsville, Alabama, United States, 35801
3
Coastal Clinical Research, Inc.
Mobile, Alabama, United States, 36608
4
Clinical Research Advantage, Inc. / Central Arizona Medical Associates, PC
Mesa, Arizona, United States, 85206